Ocular Therapeutix elects Adrienne L. Graves, Ph.D. to board effective July 10, 2023

OCULAR THERAPEUTIX, INC

Dr. Graves elected as Class I director, term until 2024 annual meeting.
Former President & CEO of Santen Inc. (US subsidiary of Japanese pharma).
Receives option to purchase 72,000 shares at $5.04/share and RSU for 24,000 shares.
Standard indemnification agreement entered upon election.
No material arrangements or transactions requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Adrienne L. Graves

member of the Board

OCUL · OCULAR THERAPEUTIX, INC

Effective: 2023-07-10
Filed: July 12, 2023, 7:59 PM ET

On July 10, 2023 (the “Effective Date”), the board of directors (the “Board”) of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Adrienne L. Graves, Ph.D., to serve as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adrienne L. Graves was elected as member of the Board at OCULAR THERAPEUTIX, INC.

Action: elected
Role: member of the Board

Exact text from the filing

On July 10, 2023 (the “Effective Date”), the board of directors (the “Board”) of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Adrienne L. Graves, Ph.D., to serve as a member of the Board, effective immediately.

View on SEC.gov

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-080180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.